These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Heat shock protein 70 / MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Ye J; Chen GS; Song HP; Li ZS; Huang YY; Qu P; Sun YJ; Zhang XM; Sui YF Cancer Immunol Immunother; 2004 Sep; 53(9):825-34. PubMed ID: 15127237 [TBL] [Abstract][Full Text] [Related]
23. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Berinstein NL Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743 [TBL] [Abstract][Full Text] [Related]
24. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536 [TBL] [Abstract][Full Text] [Related]
29. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266 [TBL] [Abstract][Full Text] [Related]
30. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Meyer RG; Britten CM; Siepmann U; Petzold B; Sagban TA; Lehr HA; Weigle B; Schmitz M; Mateo L; Schmidt B; Bernhard H; Jakob T; Hein R; Schuler G; Schuler-Thurner B; Wagner SN; Drexler I; Sutter G; Arndtz N; Chaplin P; Metz J; Enk A; Huber C; Wölfel T Cancer Immunol Immunother; 2005 May; 54(5):453-67. PubMed ID: 15627214 [TBL] [Abstract][Full Text] [Related]
31. Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy. Sypniewska RK; Hoflack L; Tarango M; Gauntt S; Leal BZ; Reddick RL; Gravekamp C Breast Cancer Res Treat; 2005 May; 91(1):19-28. PubMed ID: 15868428 [TBL] [Abstract][Full Text] [Related]
32. Natural T cell immunity against cancer. Nagorsen D; Scheibenbogen C; Marincola FM; Letsch A; Keilholz U Clin Cancer Res; 2003 Oct; 9(12):4296-303. PubMed ID: 14555498 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696 [TBL] [Abstract][Full Text] [Related]
34. Melanoma cancer vaccines and anti-tumor T cell responses. Vujanovic L; Butterfield LH J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270 [TBL] [Abstract][Full Text] [Related]
35. Recent advances in heat shock protein-based cancer vaccines. Wang HH; Mao CY; Teng LS; Cao J Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):22-7. PubMed ID: 16481277 [TBL] [Abstract][Full Text] [Related]